Physiomics (#PYC) – newly appointed board “Strategy Update”
- 2026-05-08 06:55:14
UK 00:27 Monday, 21 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Yesterday I revealed why the ghastly snobs and poltroonish incompetents at Physiomics (PYC) faced a sack the board resolution led by Mike Whitlow, aka Doc Holliday.Today a first victory for the Doc but if the board thinks it is safe it must think again.
Doc Holiday has been in touch and so I rewrite on his plans to sack the Physiomics board with added colour
Describing itself as “a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions”, Physiomics (PYC) has announced results for its half-year ended 31st December 2025 emphasising it is “delighted to report record total income for the first half of this year and believe the company is on track to meet market total income expectations”. So what about a current share price response to 0.55p, more than 15% lower?
Describing itself as “a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions”, in September-announced full year results and with its shares at 0.625p Physiomics (PYC) argued a “solid base and the board looks forward to a successful financial year 2025”. I argued otherwise and what about today placing and “retail offer” announcements?
Most recently writing on company describing itself as “a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions”, Physiomics (PYC) in July with the shares down to 0.65p I wrote ‘hopefully my warnings were heeded as shares crash on “pleased to announce” 50%-discounted fundraising!’, concluding “I suggest this latest cash not much for business development considering half-year operating expenses were above £600,000 and so, in that context, look forward to 30th June 2024 results detail”. The company now states that it “is pleased to announce its audited results for its financial year ended 30 June 2024”, but should it be?
Describing itself as “a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions”, Physiomics (PYC) commences a placing & WRAP retail offer announcement with that it “is pleased to announce that it has completed a placing, conditional on Admission”. If it is ‘pleasing’, why then a current share price response to 0.65p – more than 45% down?!
Describing itself as “a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions”, Physiomics (PYC) has issued a trading update which includes noting “a strong pipeline of potential new business” and “a high level of confidence… two large contracts… will be signed before the end of this financial year… the company would then be going into its next financial year with one of its highest ever levels of signed projects”. So what of a share price currently more than 13% lower in response at 1.3p?
Previously writing on company stating that it offers cutting edge techniques and expertise to streamline drug development journeys Physiomics (PYC), in November with the shares at 1.6p I concluded “a funding only ‘kicked a bit down the road’ avoid/sell”. So what of now results for its half-year ended 31st December 2023?
Stating that it offers cutting edge techniques and expertise to streamline drug development journeys, Physiomics (PYC) “is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government's Advancing Precision Medicine programme… we believe is a testimony to the innovative culture of our company”. Hmmm, what of a current share price of 1.6p then – down from above 5p early this year?
Shares in mathematical modelling “to help biotech and pharma companies streamline their drug development journeys” company Physiomics (PYC) closed two days ago at an unchanged 0.975p. Following “contract award” news, what of the shares currently at 1.75p and a £2.4 million market capitalisation here?
Describing itself as “a leading mathematical modelling company… to help biotech and pharma companies streamline their drug development journeys”, Physiomics (PYC) is “delighted that, having worked on a number of clinical stage projects with Bicycle (Therapeutics), we are now complementing these with a substantial project focused on earlier stage drug development”. How “substantial” is this then?
Previously writing on company describing itself as “a leading mathematical modelling company” in drug development and personalised medicine Physiomics (PYC), at the end of last month I noted a “Collaboration with The University of Sheffield” announcement helping the shares up from 2.15p to 2.30p. I though also noted that it doesn’t seem financially significant but that currently financially significant looks to be what’s needed here and still avoid/sell. Now, quelle surprise, “Equity Fundraise” announcements.
